CLEARSIDE BIOMEDICAL INC. - COMMON STOCK

Clearside Biomedical to Report Second Quarter 2023 Financial Results and Provide Corporate Update on Monday, August 14, 2023

01 Aug 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Highlights Excellent Safety Profile of CLS-AX and Potential for Extended Duration of Effect in Data Presentation at the American Society of Retina Specialists 41st Annual Scientific Meeting

31 Jul 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at Upcoming ASRS and OIS Scientific Meetings

20 Jul 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Enrollment of Multiple Participants in its ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

17 Jul 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical CEO George Lasezkay to Present at the SHARE™️ Series Investor Event on Monday, July 17, 2023

11 Jul 2023 13:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Asia-Pacific Partner Arctic Vision Announces the Acceptance in Australia of its New Drug Application for Suprachoroidal Use of Arcatus® for the Treatment of Uveitic Macular Edema

10 Jul 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Opens Enrollment in ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

01 Jun 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces First Quarter 2023 Financial Results and Provides Corporate Update

11 May 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in a Fireside Chat at the JMP Securities Life Sciences Conference

09 May 2023 13:30:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Report First Quarter 2023 Financial Results and Provide Corporate Update on Thursday, May 11, 2023

02 May 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Presents Compelling Data at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

27 Apr 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical’s Suprachoroidal Injection Platform to be Featured at The Association for Research in Vision and Ophthalmology (ARVO) 2023 Annual Meeting

19 Apr 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Plans for ODYSSEY Phase 2b Clinical Trial of CLS-AX (axitinib injectable suspension) in Wet AMD

18 Apr 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical to Participate in a Fireside Chat at the 22nd Annual Needham Virtual Healthcare Conference

12 Apr 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Enhances Scientific Advisory Board with the Appointment of Two Distinguished Retinal Physicians

05 Apr 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update

09 Mar 2023 13:05:01 By Nasdaq GlobeNewswire

Clearside Biomedical to Report Fourth Quarter and Full Year 2022 Financial Results and Provide Corporate Update on Thursday, March 9, 2023

23 Feb 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Positive Data Presentations on CLS-AX OASIS Clinical Trial and Use of SCS Microinjector® Presented at the Angiogenesis and Macula Society Annual Meetings

21 Feb 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical OASIS Data to be Presented at Multiple Upcoming Medical Meetings in February 2023

07 Feb 2023 04:05:00 By Nasdaq GlobeNewswire

Clearside Biomedical Announces Leadership Team Update

06 Feb 2023 04:30:00 By Nasdaq GlobeNewswire